BRAF mutation and age in differentiated thyroid cancer risk stratification: Two sides of the same coin
- 1 July 2020
- journal article
- editorial
- Published by Elsevier in Oral Oncology
- Vol. 106, 104732
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-UpThe Journal of Clinical Endocrinology & Metabolism, 2019
- Patient Age–Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid CancerJournal of Clinical Oncology, 2018
- BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrenceGland Surgery, 2016
- Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive IodineThe Journal of Clinical Endocrinology & Metabolism, 2016
- Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid CancerJournal of Clinical Oncology, 2015
- BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice?Endocrine, 2013
- BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical ImplicationsEndocrine Reviews, 2007
- BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2005
- Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomasCancer Letters, 2004
- BRAF mutations are associated with some histological types of papillary thyroid carcinomaThe Journal of Pathology, 2004